In this phase II study, 23 patients with metastatic breast cancer were treated with a combination of Caelyx (40mg/m(2) on day 1) and vinorelbine (20mg/m(2) on days 1 and 8) every 4 weeks. According to the statistical design, enrollment was closed after the first stage due to the low response rate observed ( four partial remissions, 12 stabilizations). Toxicity was acceptable, however, grade 3-4 neutropenia was not negligible. Our study does not support the development of this combination in advanced breast cancer.
Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer
Rimassa L;Santoro A
2003-01-01
Abstract
In this phase II study, 23 patients with metastatic breast cancer were treated with a combination of Caelyx (40mg/m(2) on day 1) and vinorelbine (20mg/m(2) on days 1 and 8) every 4 weeks. According to the statistical design, enrollment was closed after the first stage due to the low response rate observed ( four partial remissions, 12 stabilizations). Toxicity was acceptable, however, grade 3-4 neutropenia was not negligible. Our study does not support the development of this combination in advanced breast cancer.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
aa.pdf
non disponibili
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
51.36 kB
Formato
Adobe PDF
|
51.36 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
